Recombinant probiotic bacteria for the prevention and treatment of inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS)
View Patent ↗The present invention relates to the general field of therapy of Inflammatory Bowel Disease (IBD) and/or Irritable Bowel Syndrome (IBS). Thus, the invention relates to a molecule selected from the trappin-2 protein or an active fraction thereof, a member of the WAP family proteins or an active fraction thereof or a member of the Serpin family proteins or an active fraction thereof for the treatment of Irritable Bowel Syndrome (IBS). The invention also relates to a recombinant food-grade bacterium comprising a gene selected from a gene coding for the trappin-2 protein or an active fraction thereof, a gene coding for a member of the WAP family proteins or an active fraction thereof, or a gene coding for a member of the Serpin family proteins or an active fraction thereof.
1. A recombinant food-grade Lactobacillus casei bacterium consisting essentially of a recombinant gene comprising a nucleic acid sequence encoding (a) a signal peptide of Usp45 protein and (b) the active fraction of the elafin protein, wherein the recombinant bacterium expresses and secretes the active fraction of the elafin protein, and wherein the active fraction exhibits trypsin-like and elastase-like activity.
2. The recombinant food-grade Lactobacillus casei bacterium of claim 1 , wherein the bacterium comprises a defective thyA auxotrophic gene.
3. The recombinant food-grade Lactobacillus casei bacterium of claim 2 , wherein the said recombinant gene is inserted in the defective auxotrophic gene.
4. A therapeutic composition comprising the food grade Lactobacillus casei bacterium according to claim 1 , 2 or 3 .
5. A food composition comprising the food-grade Lactobacillus casei bacterium according to claim 1 , 2 or 3 .
6. The recombinant food-grade Lactobacillus casei bacterium of claim 1 , wherein the recombinant gene coding for said active fraction of the elafin protein has the sequence of a product obtained by PCR amplification of a plasmid encoding the elafin gene, wherein the PCR amplification utilizes a 5′ forward-Elafin primer having the sequence according to SEQ ID NO: 1, and a 3′ reverse-Elafin primer having the sequence according to SEQ ID NO: 2.